Catalog No. :	CL2211
Product Name :	Osimertinib
CAS No. :	1421373-65-0
Synonyms :	Mereletinib | AZD-9291
Chemical Name :	N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Molecular Formula :	C28H33N7O2
Molecular Weight :	499.62
Molecular Structure :
Appearance :	Off-white powder
Specification :	98+%
Application :	Anti-cancer research | EGFR
Registration :
Storage Condition :	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Osimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. Osimertinib was approved in Nov. 2015 by FDA.

Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.